Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Carlo Patrono

Showing results (31-40 of 257) with videos related to

Pageof 26
Sort By:
European Heart Journal|May 4, 2023
Targeting residual cardiovascular risk in the statin era: cholesterol or inflammation?Giovanna Liuzzo, Carlo Patrono
Arteriosclerosis, Thrombosis, and Vascular Biology|October 16, 2002
Cyclooxygenase-2 polymorphism: putting a brake on the inflammatory response to vascular injury?Francesco Cipollone, Carlo Patrono
European Heart Journal|November 11, 2025
Weekly Journal Scan: Ischaemic vs bleeding risk early after myocardial infarction-which should we TARGET FIRST?Rocco Vergallo, Carlo Patrono
European Heart Journal|January 9, 2025
Weekly Journal Scan: no CLEAR evidence of cardiovascular benefits of colchicine after acute myocardial infarctionGiovanna Liuzzo, Carlo Patrono
European Heart Journal|March 25, 2025
Weekly Journal Scan: Is there adequate evidence for targeting only one pathway of platelet activation shortly after an acute coronary syndrome?Giovanna Liuzzo, Carlo Patrono
European Heart Journal|November 9, 2025
Weekly Journal Scan: Rethinking dual antiplatelet therapy after coronary artery bypass grafting for acute coronary syndromesGiovanna Liuzzo, Carlo Patrono
European Heart Journal|November 9, 2025
Weekly Journal Scan: spironolactone does not ACHIEVE reduction of cardiovascular outcomes in dialysis patientsDaniela Pedicino, Carlo Patrono
Biochimica Et Biophysica Acta|September 30, 2014
Cyclooxygenase inhibitors: From pharmacology to clinical read-outsPaola Patrignani, Carlo Patrono
European Heart Journal|October 25, 2020
Aspirin Monotherapy vs. DAPT after TAVI: Is Less More? Comment on the POPular TAVI TrialLeonarda Galiuto, Carlo Patrono
European Heart Journal|November 21, 2020
The widely promoted antimalarial drug hydroxychloroquine confers no mortality benefit in hospitalized patients with COVID-19: comment on the 'Effect of Hydroxychloroquine in Hospitalized Patients with COVID-19'Giovanna Liuzzo, Carlo Patrono
Pageof 26

Showing results (31-40 of 257) with videos related to

Sort By:
Pageof 26
European Heart Journal|May 4, 2023
Targeting residual cardiovascular risk in the statin era: cholesterol or inflammation?Giovanna Liuzzo, Carlo Patrono
Arteriosclerosis, Thrombosis, and Vascular Biology|October 16, 2002
Cyclooxygenase-2 polymorphism: putting a brake on the inflammatory response to vascular injury?Francesco Cipollone, Carlo Patrono
European Heart Journal|November 11, 2025
Weekly Journal Scan: Ischaemic vs bleeding risk early after myocardial infarction-which should we TARGET FIRST?Rocco Vergallo, Carlo Patrono
European Heart Journal|January 9, 2025
Weekly Journal Scan: no CLEAR evidence of cardiovascular benefits of colchicine after acute myocardial infarctionGiovanna Liuzzo, Carlo Patrono
European Heart Journal|March 25, 2025
Weekly Journal Scan: Is there adequate evidence for targeting only one pathway of platelet activation shortly after an acute coronary syndrome?Giovanna Liuzzo, Carlo Patrono
European Heart Journal|November 9, 2025
Weekly Journal Scan: Rethinking dual antiplatelet therapy after coronary artery bypass grafting for acute coronary syndromesGiovanna Liuzzo, Carlo Patrono
European Heart Journal|November 9, 2025
Weekly Journal Scan: spironolactone does not ACHIEVE reduction of cardiovascular outcomes in dialysis patientsDaniela Pedicino, Carlo Patrono
Biochimica Et Biophysica Acta|September 30, 2014
Cyclooxygenase inhibitors: From pharmacology to clinical read-outsPaola Patrignani, Carlo Patrono
European Heart Journal|October 25, 2020
Aspirin Monotherapy vs. DAPT after TAVI: Is Less More? Comment on the POPular TAVI TrialLeonarda Galiuto, Carlo Patrono
European Heart Journal|November 21, 2020
The widely promoted antimalarial drug hydroxychloroquine confers no mortality benefit in hospitalized patients with COVID-19: comment on the 'Effect of Hydroxychloroquine in Hospitalized Patients with COVID-19'Giovanna Liuzzo, Carlo Patrono
Pageof 26